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Summary
Introduction. Major osteoporotic fractures are steadily
increasing due to population aging. Programs of sec-
ondary prevention against refracture are essential to de-
crease morbidity and mortality and the cost for individu-
als and the society. Vitamin D supplementation and opti-
mization of calcium intake are of a pivotal importance to
start specific osteoporosis treatment and for its safety
and efficacy. Cholecalciferol is the most widely em-
ployed drug for vitamin D supplementation, 
Purpose. Aim of this study was to assess the trends in
the use of vitamin D supplements containing cholecalcif-
erol in the population of hip fracture patients older than
65 years, resident in the region of Tuscany (Italy) in the
years 2011-2015 and to describe vitamin D status in a
subgroup of this individuals directly referred to a bone
clinic for further evaluation after hip osteoporotic frac-
ture.
Methods. Data were retrieved from the electronic anony-
mous regional administrative database administered by
the Region of Tuscany (Italy) in the years 2011-2015
within the T.A.R.Ge.T. project (Trattamento Appropriato
delle Rifratture Geriatriche in Toscana, i.e., “Appropriate
treatment of geriatric refractures in Tuscany”), a pro-
gram endorsed by the region itself. Data pertaining to
cholecalciferol prescriptions and hospital discharge
codes were retrieved and appropriately crossed to get
data on the use of cholecalciferol supplements in pa-
tients before and after a hip fracture. 
A retrospective analysis was carried out in a subgroup
of subjects (n 254) appropriately referred to the local
fracture liaison service after the major osteoporotic frac-
ture and vitamin D status in terms of serum 25(OH) vita-
min D levels was assessed.
Results. The majority of subjects experiencing a hip
fracture (98.2% and 88.3% in 2011 and 2015, respective-
ly) did not receive vitamin D supplements at the time of
the fracture event. Although a trend in increase in pre-
scriptions for cholecalciferol supplements could be ob-
served in the years of the study, the percentage of treat-
ed individuals remained low even after the fracture,
since only 30-35% of subjects receives cholecalciferol
supplements at one year after the fracture. Cholecalcif-
erol remained the most prescribed drug in this popula-
tion, while a substantial decrease of cholecalciferol in
association with calcium salts was observed. The use of
high doses of cholecalciferol has decreased in this pop-
ulation, while diminished the use of the drops has been
accompanied by an increase in prescriptions of single
monthly dose supplements.
Conclusions. The correction of vitamin D inadequacy is
preliminary to any treatment for osteoporosis and to-
gether with calcium may reduce fracture risk by itself.
The prescription of vitamin D supplements is low in pa-
tients before and after a hip fracture in a Mediterranean
region and despite the overall increase in vitamin use
and abuse in the general population. Proper educational
programs and active fracture liaison services are needed
in order to bridge this gap.
KEY WORDS: vitamin D; osteoporosis; aging; prevention; nutrition; calcium in-
take; frailty.
Introduction
Optimal vitamin D status is essential for the absorption of
calcium and phosphate necessary to preserve mineral home-
ostasis and bone health and to maintain skeletal muscle per-
formance (1, 2). Cholecalciferol (vitamin D3) is the most
widely employed supplement to correct vitamin D deficiency
and to maintain steadily serum 25(OH) vitamin D [25(OH)D]
levels above the thresholds of 20 or 30 ng/ml, which have
been set for bone health by international consensus guide-
lines. Many studies have demonstrated the efficacy, safety
and tolerability of cholecalciferol, when employed at physio-
logical, non-toxic doses (3, 4). Further trials are needed to
assess the possible non-classic toxic effects of cholecalcifer-
ol such as the increase in number of falls observed in some
studies employing high, concentrated doses of vitamin D
[25(OH)]. For these reason, cholecalciferol supplements are
nowadays recommended for the treatment of vitamin D defi-
ciency at common doses in patients with musculoskeletal
diseases, while their use in extra-skeletal chronic disorders
and the employment of high amounts are debated (5). The
characteristics of safety and efficacy, together with the sup-
posed benefits of cholecalciferol in the prevention and treat-
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ment of extra skeletal diseases, have meant that the pre-
scription of cholecalciferol both by specialists and general
practitioners is greatly increased during the last decade (6). 
The correction and maintenance of vitamin D sufficiency, to-
gether with the optimization of calcium intake, are prelimi-
nary to any treatment for osteoporosis in both sexes (7, 8).
Figures of osteoporotic fractures are steadily increasing
worldwide due to the ageing of the population (9). Indeed,
the occurrence of major osteoporotic fractures requires the
initiation of secondary prevention strategies aimed to in-
crease bone strength and prevent further fractures. Nonethe-
less, in the absence of effective fracture liaison services be-
tween orthopedic departments and bone clinics, the under-
taking of such programs is often difficult. Bone antiresorptive
and proformative agents are effective in preventing further
fractures when prescribed after the occurrence of fragility
fractures as agents for secondary prevention (7). The effica-
cy and safety of osteoporosis therapy is strongly related to
vitamin D status and calcium intake. Indeed, the correction
of vitamin D deficiency prevents adverse events such as an-
tiresorptive-related hypocalcemia and improves their efficacy
in reducing fracture risk. For these reasons is commonly be-
lieved that the optimization of both vitamin D status and cal-
cium intake has to precede the start of antifracture therapy.
Besides the use of vitamin D supplements is widespread in
the population, the assumption of vitamin D is still low in
people experiencing osteoporotic fractures, even in some
countries of regions in which population-based interventions
are directed especially towards elderly people. Recent stud-
ies have pointed out that only a small percentage of elderly
people experiencing hip fractures receive vitamin D supple-
mentation at the time of the event and the vast majority of
them is vitamin D deficient (10-12). Such data are lacking in
Italy.
Aim of this study was to evaluate the pattern of prescription
of vitamin D supplements and, in particular, cholecalciferol in
an Italian region (region of Tuscany), as representative of a
Mediterranean country, in the population of hip fracture pa-
tients, before and after the event, and vitamin D status in a
subgroup of these patients surgically treated and medically
managed in a tertiary referral center.
Methods
Data were extracted from the electronic anonymous regional
administrative database administered by the Region of Tus-
cany (Italy) in the years 2011-2015. This database was built
to monitor and control health expenditure of the whole popu-
lation of Tuscany (whole population: 3,749,813 and
3,752,654 inhabitants in 2011 and 2015, respectively; adults
>65 years, 872,766 in 2011 and 929,050 in 2015), including
information for statistical and epidemiological analyses. Pa-
tients over 65 years of age were included in this analysis, ac-
cording to the aims of the T.A.R.Ge.T. project (Trattamento
Appropriato delle Rifratture Geriatriche in Toscana, i.e., “Ap-
propriate treatment of geriatric refractures in Tuscany”), a
program endorsed by the Region of Tuscany (13). 
Data pertaining to cholecalciferol prescriptions (expressed
as number of individuals receiving cholecalciferol) both by
hospitals and general practitioners were retrieved as related
to the years 2011-2015 in order to estimate the consumption
of vitamin D supplements in patients experiencing a hip frac-
ture and after hip fracture. Prescriptions for marketed vitamin
D compounds containing cholecalciferol commonly used in
clinical practice (cholecalciferol alone or in combination with
calcium carbonate or alendronate) were extracted according
to the number of the Anatomical Therapeutic Chemical clas-
sification system of drugs, group 5 [ATC5: cholecalciferol
(A11CC05), cholecalciferol in combination with calcium
(A12AX), and cholecalciferol in combination with alendronate
(M05BB03)]. An analysis for the way of cholecalciferol ad-
ministration was also carried out. For cholecalciferol, an
analysis of way of administration (drops 10,000 IU/10ml ad-
ministered orally, vials, 25,000 or 50,000 IU bottles adminis-
tered orally, 100,000 IU or 300,000 IU vials administered
orally or intramuscularly) was performed.
The flow of data related to prescriptions was properly
crossed and longitudinally analyzed with data pertaining to
the flow of data containing medical discharge codes and
general data flow, in order to restrict the analysis to the pop-
ulation of seniors with hip fracture of both sexes. Hip frac-
tures were defined by the following ICD-9-CM diagnosis
codes assigned at discharge as major diagnosis: 820.0-
820.1 (femoral neck fractures), 820.2-820.3 (pertrochanteric
femoral fractures) and 820.8, 820.9 and 821.1 (other femoral
fractures). Patients with diagnosis codes of Paget’s disease
(ICD-9-CM 731) and neoplasm (ICD-9-CM 140-239) were
excluded. Hip fractures caused by road accident or trauma
were not included in the analysis. The time of hip fracture
was also retrieved in order to establish two separate analy-
ses regarding the period immediately before and after the
fracture event.
For the longitudinal study of prescriptions related to the year
2015, only patients fractured within the first 6 months were
considered in the analysis in order to have a minimum follow
up of 6 months. 
A subgroup of 254 consecutive patients referred after hip
fracture to the Unit of Bone and Mineral Diseases of the Uni-
versity Hospital of Florence (Florence, Italy) for secondary
prevention programs within the local Fracture Liaison Ser-
vice were retrospectively evaluated in a two-year period
(2015-2016) for baseline vitamin D status and records of vit-
amin D supplementation at the time of the fracture. Baseline
serum 25(OH)D levels were referred to the record at pre-sur-
gical screening or at the first medical assessment usually
taking place within the first 2-3 months after hip surgery, as
part of the baseline assessment for osteoporosis. Data were
expressed as percentage of total and as mean ± SD. Statisti-
cal significances were computed by using the test on propor-
tions.
This study was approved by the Internal Review Board of the
University Hospital of Florence.
Results
Elderly patients (over 65 years of age), resident in the Re-
gion of Tuscany and suffering hip fractures in the years
2011-2015 were considered for this analysis.
Within this group, in the 5 years of the study, the number of
patients experiencing hip fracture rose from 5818 in 2011
(0.7% of resident elderly population) to 6686 in 2015 (0.7%
of resident elderly population) (Table 1), with a female: male
ratio of about 3 : 1 (females: 75.9-77.8%, males: 22.2-
24.1%) and a mean age at the time of the fracture of 83.3
years.
The proportion of patients under vitamin D3 supplementation
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at the time of the fracture was estimated. Only 1.8%
(104/5818) of individuals with hip fracture were receiving
cholecalciferol before the fracture event in 2011. This per-
centage has significantly increased over the years, being
11.7% in 2015 (p=0.0376) (Table 1).
As shown in Table 1 and Figure 1, the proportion of patients
commencing cholecalciferol after hip fracture significantly
rose within the year after the fracture event from 8.1% at 1
month after the fracture event, to 18.9% after 3 months, to
23.8% at 6 months and to 28.1% at one year in 2011 (p<
.001). This trend was confirmed within each year of the
study. The percentage of patients on vitamin D supplements
at 1 month rose significantly along the years of observation
(from 8.1% in 2011 to 11.8% in 2015), while the percentage
hip fracture patients on vitamin D supplements at 6 months
and one year did not change significantly over time and a
decreasing trend was even observed.
As far as the type of drug is concerned, cholecalciferol alone
(A11CC05) was the most prescribed vitamin D supplement al-
ready in 2011 and its use further increased in a significant way
in the 5 year of observation (p=< .001), while the use of chole-
calciferol in combination with calcium salts (A12AX) decreased
markedly, almost half half-dying, during the 5 years (p=.001)
(Table 2). The association of cholecalciferol and alendronate
(M05BB03) was by far the less prescribed form of cholecalcif-
erol and decreased further during the study period, although
not significantly (Table 2). No statistical differences were ob-
served between sexes with respect to these parameters.
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Table 1 - Patients with hip fractures in the Region of Tuscany in the years 2011-2015 are reported. Within this population, patients on vitamin D sup-
plements before the hip fracture (Fx) and patients receiving vitamin D supplements at one, two, three, six and twelve months after the major osteo-
porotic fracture are shown; patients are expressed as number and percentage of the total hip fracture patients each year; p refers to values in 2015
as compared to values in 2011; ns=not significant.*For 2015 only patients fractured in the first 6 months were considered to have a maximum follow
up of 6 months to analyze vitamin D prescriptions; therefore data at 12 months are not available.
2011 2012 2013 2014 2015 p




before hip Fx 





- at 1 month 472 8.1% 472 8.3% 751 12.2% 773 12.2% 792 11.8% ns
- at 2 months 1098 18.9% 1087 19.2% 1489 24.2% 1524 24.0% 1458 21.8% ns
- at 6 months 1386 23.8% 1374 24.3% 1812 29.4% 1884 29.7% 1686 25.2% ns
- at 12 months 1646 28.3% 1633 28.8% 2093 34.0% 2174 34.3% —-* —-* —*
Figure 1 - Patients on vitamin D supplements containing cholecalciferol after 1 month, 3 months, 6 months and one year after hip fracture in the Re-
gion of Tuscany in the years 2011-2015. 
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In the analysis carried out on the treatment modality for
cholecalciferol alone (A11CC05), cholecalciferol drops were
the most prescribed in 2011, but their use significantly de-
creased during the years of observation (p< .001), in parallel
to the increase of prescription of 25,000 IU single-dose
cholecalciferol, which was the most prescribed form in 2015
(p< .001) (Figure 2). The use of high concentrated doses of
vitamin D (i.e. 300,000 IU vials) decreased substantially in
the study period (p< .001), while the prescription of 100,000
IU vials slightly rose from 2011 to 2015 (< .001) (Figure 2). 
In the retrospective analysis on the 254 consecutive patients
(73.2% women, 26.8% men, mean age 82.9±9.1 years) eval-
uated after surgical treatment for hip fracture, baseline (i.e.
recorded at first medical evaluation after within 2-3 months
after the fracture event) serum 25(OH)D levels were record-
ed and analyzed. Mean serum levels of 25(OH)D were
13.7±9.8 ng/ml, with no statistical differences between men
and women. Only 20.9% had serum 25(OH)D levels above
20 ng/ml and just 7.1% of hip fracture patients had serum
25(OH)D levels above 30 ng/ml (Figure 3). The majority of
individuals (42.9%) was severely vitamin D deficient [i.e.
serum 25(OH)D levels below 10 ng/ml] at the time of the hip
fracture (Figure 3). In this group of hip fracture patients,
15.0% was receiving vitamin D supplements at baseline.
Discussion
Figures of hip fracture are constantly growing in the popula-
tion due to population aging (9).
Despite the widespread and steadily increasing use of vita-
min D supplements in the population, often dispensed for a
variety of diseases (5, 6), this study shows that the intake of
vitamin D supplements by subjects either experiencing or
having experienced a major osteoporotic fracture, such as a
hip fracture, remains low at the time of the event and even
after. 
The analysis on the data retrieved by a regional prescription
database in a Mediterranean country and the subgroup retro-
spective survey in patients addressed to medical manage-
ment of osteoporosis in an Italian tertiary referral center,
confirmed previous data showing that only a small percent-
age of individuals was taking vitamin D supplements at the
time of the major osteoporotic fracture (10-12). Just 1.8% of
the total patients experiencing a hip fracture in Tuscany in
2011 (104 on vitamin D supplementation/5818 hip fracture
patients) was under cholecalciferol treatment at baseline.
This percentage increased during the years, to reach 11.7%
in 2015 (783 on vitamin D supplementation/6686 hip fracture
patients). Thus, the use of cholecalciferol has steadily in-
creased during the last years. While only 1:50 patients with
hip fracture was on vitamin D supplementation in 2011, 1:10
individuals experiencing hip fracture was receiving cholecal-
ciferol supplementation at the time of the fracture in 2015.
This might reflect the vitamin D supplementation strategies
in the elderly populations applied in some regions by the lo-
cal health system, but it may be due also to increased
awareness of the need of vitamin D supplementation in peo-
ple at high risk for fracture.
The prescription of vitamin D, which has to be strongly ad-
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Figure 2 - Treatment modality with cholecalciferol supplements in the years in Region of Tuscany in the years 2011-2015 in the total population of hip
fracture patients receiving vitamin D supplements. Data referring to the 50,000 IU cholecalciferol bottle were obtained just for 2015, since its introduction
on the market.
Table 2 - Percentage of individuals prescribed with different cholecalciferol pharmaceutical specialties identified by specific ATC5 codes in the Re-
gion of Tuscany in the years 2011-2015; p refers to values in 2015 as compared to values in 2011.
Drug ATC5 code 2011 2012 2013 2014 2015 p
Cholecalciferol A11CC05 46.2% 48.7% 51.8% 58.9% 61.7% p<.001
Cholecalciferol + calcium salts A12AX 42.7% 39.6% 36.8% 32.1% 29.2% p<.001
Cholecalciferol + alendronate M05BB03 11.0% 11.7% 11.4% 8.9% 9.1% p=ns
100.0% 100.0% 100.0% 100.0% 100.0%
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vised in these patients at high risk for further fractures, in-
creased significantly within the year after the fracture, but it
plateaued at around 30-35%. Still, 7:10 patients did not re-
ceive any vitamin D supplement at one year after the frac-
ture and, likely, did not take any osteoporotic drug. This
trend was maintained for all the 5 years of observation. The
slight increase in the number of patients prescribed with vita-
min D supplements in the first months after hip fracture
might refers to the group of subjects appropriately referred to
fracture liaison services activated within the hospitals where
the orthopedic treatment for hip fracture was first performed.
Indeed, group of patients can be appropriately referred to
these services for the commencement of programs of sec-
ondary prevention of re-fracture (14). These procedures
have to be encouraged and reinforced in order to address
these patients towards effective programs of secondary pre-
vention against refracture. The retrospective analysis on a
subgroup of patients referred to such a service within the
hospital soon after the fracture, demonstrate that even in a
Mediterranean country such as Italy almost a half of patients
experiencing a hip fracture is severely vitamin D deficient
and only less than 10% have serum 25(OH)D levels above
30 ng/ml, which is considered the  threshold to be achieved
in subjects at high risk for fracture (15). Since vitamin D suf-
ficiency is required to begin osteoporotic therapy, given the
high prevalence of vitamin D deficiency in elderly people
throughout the year even in Mediterranean countries such as
Italy, elders experiencing a major osteoporotic fracture such
a hip fracture or at high risk for fracture should receive vita-
min D supplementation straight away, despite waiting for the
determination of serum 25(OH)D levels (7, 15-17). In the ret-
rospective survey, only 15.0% of patients received cholecal-
ciferol at the time of the fracture event. Since these patients
were addressed to the secondary prevention programs with-
in the fracture liaison service in tertiary referral centers, they
were then prescribed or reinforced with vitamin D supple-
ments in order to later support osteoporotic therapy. In a lon-
gitudinal analysis (data not shown), almost all patients were
assuming vitamin D preparations one year after hip fracture,
demonstrating the high adherence to this supplement.
Cholecalciferol alone was by far the most employed vitamin
D supplement in patients with hip fracture, and its use further
increased in the 5 years of the study, reflecting the trend in
the general population (6). In parallel, the use of cholecalcif-
erol in association with calcium salts has significantly de-
creased over time, reflecting the substantial reduction of the
use of calcium supplements in the last years because of side
effects and/or the fear for possible increased risk for vascu-
lar calcifications. Also cholecalciferol in association with al-
endronate has decreased, although not significantly, and this
may be a sign of the constant reduction of the usage of anti-
osteoporosis drugs, even in patients at high risk for fracture
(18).
Interesting results were observed regarding the way of ad-
ministration of cholecalciferol alone. While in 2011 the use of
drops of cholecalciferol was the preferred way of vitamin D
supplementation, an increase in the use of 25,000 IU single-
dose cholecalciferol, usually administered monthly, was doc-
umented, so that it has progressively become the supple-
ment of choice in the whole population of patients with hip
fracture during the years of the survey. Remarkably, the use
of high concentrated cholecalciferol supplements (300,000
IU vials) has gradually decreased. This may be due to the in-
creased awareness of the possible side-effects (i.e. falls) of
high doses of vitamin D3 (19). At the same time, a rise in pre-
scriptions of 100,000 IU cholecalciferol vials has been
recorded. All in all, the use of high concentrated forms of
cholecalciferol remains low.
Conclusion
Vitamin D inadequacy is highly prevalent in patients experi-
encing a major osteoporotic fracture such a hip fracture. The
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Figure 3 - Vitamin D status in a population hip fracture patients (n 254) evaluated soon after the fracture event (up to 3 months after hip fracture), at
the first evaluation in a tertiary referral center with a fracture liaison service (University Hospital of Florence): proportion of patients with serum 25(OH)
vitamin D [(25(OH)D] levels above 30 ng/ml (vitamin D sufficient), between 20 and 30 ng/ml (vitamin D insufficient), between 10 and 20 ng/ml (vita-
min D deficient) and below 10 ng/ml (severely vitamin D deficient).
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use of vitamin D supplements is low in patients admitted to
surgical departments for the treatment of hip fractures and
remains low after the event. The results of this study per-
formed in a Mediterranean region confirm previous results
obtained in other countries.
There is therefore the need to reinforce the use of vitamin D,
along with proper nutritional advice for sufficient calcium in-
take, for optimal musculoskeletal health and prevention pro-
grams. Fracture liaison services activated in the hospital tak-
ing care of the hip fracture patients, along with specific edu-
cational interventions for the patients themselves and gener-
al practitioners, can be the turning point to ameliorate vita-
min D and nutrition status in this category of subjects. These
interventions are a good start for commencing efficacious
programs against re-fracture to decrease further disability
and decreasing costs for the individuals and the community.
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